| 000 | 01909 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517152046.0 | ||
| 264 | 0 | _c20180302 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdx069 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGuberina, M | |
| 245 | 0 | 0 |
_aHeart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _c05 2017 |
||
| 300 |
_a1084-1089 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xmortality |
| 650 | 0 | 4 |
_aChemoradiotherapy _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Radiation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart _xradiation effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xmortality |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyocardium _xpathology |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aRadiation Injuries _xdiagnosis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aEberhardt, W | |
| 700 | 1 | _aStuschke, M | |
| 700 | 1 | _aGauler, T | |
| 700 | 1 | _aHeinzelmann, F | |
| 700 | 1 | _aCheufou, D | |
| 700 | 1 | _aKimmich, M | |
| 700 | 1 | _aFriedel, G | |
| 700 | 1 | _aSchmidberger, H | |
| 700 | 1 | _aDarwiche, K | |
| 700 | 1 | _aJendrossek, V | |
| 700 | 1 | _aSchuler, M | |
| 700 | 1 | _aStamatis, G | |
| 700 | 1 | _aPöttgen, C | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 28 _gno. 5 _gp. 1084-1089 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdx069 _zAvailable from publisher's website |
| 999 |
_c27123923 _d27123923 |
||